Live Breaking News & Updates on Greg Zante

Stay updated with breaking news from Greg zante. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Target Price at $30.25

Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Target Price at $30.25
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Sarah Kathryn Rouan , Greg Zante , Swiss National Bank , York Mellon Corp , Dimensional Fund Advisors , Therapeutics Inc , Therapeutics Company Profile , Blackrock Inc , Jpmorgan Chase Co , Viking Therapeutics , Get Free Report , Marketbeat Ratings , Director Sarah Kathryn Rouan , National Bank , New York Mellon Corp , Fund Advisors , Get Free , Viking Therapeutics Daily ,

Knights of Columbus Asset Advisors LLC Boosts Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Knights of Columbus Asset Advisors LLC raised its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 3.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,557 shares of the biotechnology company’s stock after purchasing an additional 1,226 shares […] ....

Sarah Kathryn Rouan , Greg Zante , Sg Americas Securities , Therapeutics Company Profile , Swiss National Bank , Oppenheimer Co , Securities Exchange Commission , Principal Financial Group Inc , Columbus Asset Advisors , Victory Capital Management Inc , Therapeutics Inc , Viking Therapeutics , Free Report , Capital Management , Financial Group , National Bank , Exchange Commission , Director Sarah Kathryn Rouan , Get Free Report , Viking Therapeutics Daily , Nasdaq Vktx , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 15,000 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CFO Greg Zante sold 15,000 shares of Viking Therapeutics stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $17.90, for a total transaction of $268,500.00. Following the completion of the transaction, the chief financial officer now directly owns 180,730 […] ....

Greg Zante , Balyasny Asset Management , Vanguard Group Inc , Securities Exchange Commission , Blackrock Inc , Therapeutics Inc , Viking Therapeutics , Get Free Report , Exchange Commission , Street Corp , Asset Management , Viking Therapeutics Daily , Nasdaq Vktx , Insider Trading , Nsider Trades ,

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Call Transcript

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2023 Earnings Call Transcript October 25, 2023 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.23 EPS, expectations were $-0.22. Operator: Welcome to the Viking Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we […] ....

Greg Zante , Exchange Commission , Obesity Society , Brian Lian , Chief Financial , Glucagon Like Peptide , Glucose Dependent Insulinotropic Polypeptide , Productive States , Rich People Own Real , Viking Therapeutics , Viking Therapeutics , Stephanie Diaz , Financial Results , Greg Zante , Nine Months ,